PRAXIS PRECISION MEDICINES, INC. Payments to Acquire Debt Securities, Available-for-sale
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Payments to Acquire Debt Securities, Available-for-sale of $564.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $77.27M, a 86.88% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $486.78M, a 315.85% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $390.27M, a 462.21% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $75.13M, a 528.25% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $623.81M, a 67.91% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $371.52M.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $83.02M, a 49.43% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $77.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $564.05M 10-Q · filed 2026-08-06 | $954.33M derived: sum of 3 quarters · filed 2026-08-06 | $1.03B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $486.78M 10-Q · filed 2026-05-07 | $877.06M derived: sum of 2 quarters · filed 2026-05-07 | $952.19M derived: sum of 3 quarters · filed 2026-05-07 | $993.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $390.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $465.41M derived: sum of 2 quarters · filed 2026-02-19 | $506.75M derived: sum of 3 quarters · filed 2026-08-06 | $623.81M 10-K · filed 2026-02-19 |
| 2025-09-30 | $75.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $116.48M derived: sum of 2 quarters · filed 2026-08-06 | $233.54M 10-Q · filed 2025-11-05 | $302.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $41.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $158.40M 10-Q · filed 2026-08-06 | $227.82M derived: sum of 3 quarters · filed 2026-08-06 | $239.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $117.06M 10-Q · filed 2026-05-07 | $186.47M derived: sum of 2 quarters · filed 2026-05-07 | $198.43M derived: sum of 3 quarters · filed 2026-05-07 | $397.36M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $69.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $81.38M derived: sum of 2 quarters · filed 2026-02-19 | $280.30M derived: sum of 3 quarters · filed 2026-02-19 | $371.52M 10-K · filed 2026-02-19 |
| 2024-09-30 | $11.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $210.88M derived: sum of 2 quarters · filed 2025-11-05 | $302.10M 10-Q · filed 2025-11-05 | $302.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $198.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $290.14M 10-Q · filed 2025-08-04 | $290.14M derived: sum of 3 quarters · filed 2026-02-19 | $290.14M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $91.22M 10-Q · filed 2025-05-02 | $91.22M derived: sum of 2 quarters · filed 2026-02-19 | $91.22M derived: sum of 3 quarters · filed 2026-02-19 | $91.22M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $83.02M 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $83.02M 10-Q · filed 2023-11-07 | $83.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $83.02M 10-Q · filed 2023-08-09 | $83.02M derived: sum of 3 quarters · filed 2023-08-09 | $83.02M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $83.02M 10-Q · filed 2023-05-11 | $83.02M derived: sum of 2 quarters · filed 2023-05-11 | $83.02M derived: sum of 3 quarters · filed 2023-05-11 | $107.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $0.00 derived: sum of 2 quarters · filed 2023-02-07 | $24.16M derived: sum of 3 quarters · filed 2023-02-07 | $164.17M 10-K · filed 2023-02-07 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $24.16M derived: sum of 2 quarters · filed 2022-11-09 | $164.17M 10-Q · filed 2022-11-09 | $164.17M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $24.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $164.17M 10-Q · filed 2022-08-08 | $164.17M derived: sum of 3 quarters · filed 2022-08-08 | $164.17M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $140.01M 10-Q · filed 2022-05-09 | $140.01M derived: sum of 2 quarters · filed 2022-05-09 | $140.01M derived: sum of 3 quarters · filed 2022-05-09 | $140.01M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |